Jove
Visualize
Contact Us

Related Experiment Videos

Pneumococcal vaccination: current and future issues.

A Ortqvist1

  • 1Karolinska Institutet and Dept of Infectious Diseases, Karolinska Hospital, Stockholm, Sweden.

The European Respiratory Journal
|August 21, 2001
PubMed
Summary

Effective vaccines against Streptococcus pneumoniae are crucial. While polysaccharide vaccines benefit some, conjugate vaccines show promise in young children, potentially curbing antibiotic resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

More than time: travel time to the delivery ward and maternal outcomes - onset of labour, postpartum haemorrhage and obstetric anal sphincter injury.

Public health·2023
Same author

The changing epidemiology of community-acquired pneumonia: nationwide register-based study in Sweden.

Journal of internal medicine·2019
Same author

A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.

Journal of internal medicine·2015
Same author

Knowledge and understanding of antibiotic resistance and the risk of becoming a carrier when travelling abroad: a qualitative study of Swedish travellers.

Scandinavian journal of public health·2015
Same author

Prevailing effectiveness of the 2009 influenza A(H1N1)pdm09 vaccine during the 2010/11 season in Sweden.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2013
Same author

Guidelines for the management of adult lower respiratory tract infections--summary.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2011
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Medical Microbiology
  • Vaccinology
  • Infectious Diseases

Background:

  • Streptococcus pneumoniae infections pose a significant global health challenge.
  • Existing 23-valent polysaccharide vaccines are effective against pneumococcal pneumonia in young adults but less so in the elderly.
  • The polysaccharide vaccine demonstrates efficacy in preventing invasive pneumococcal disease in the elderly and certain immunocompromised individuals.

Purpose of the Study:

  • To review the efficacy of current Streptococcus pneumoniae vaccines.
  • To assess the role of vaccines in preventing pneumococcal disease across different age groups and immune statuses.
  • To evaluate the potential of new conjugate vaccines in controlling invasive disease and antibiotic resistance.

Main Methods:

  • Review of existing literature on Streptococcus pneumoniae vaccines.
  • Analysis of vaccine efficacy data in immunocompetent and immunocompromised populations.
  • Evaluation of polysaccharide and polysaccharide-protein conjugate vaccine performance.

Main Results:

  • The 23-valent polysaccharide vaccine is recommended for older adults and high-risk children over 2 years, with revaccination advised after 5 years.
  • Polysaccharide vaccines are effective in preventing invasive pneumococcal disease in the elderly and some immunocompromised groups.
  • New polysaccharide-protein conjugate vaccines (7-11 serotypes) show effectiveness in children under 2 for invasive disease, severe pneumonia, and otitis media, and target serotypes linked to penicillin resistance.

Conclusions:

  • Vaccination remains a key strategy for preventing Streptococcus pneumoniae infections.
  • Polysaccharide vaccines have a defined role in specific populations, while conjugate vaccines offer potential for broader protection and combating antibiotic resistance in young children.
  • Despite limitations like serotype coverage and cost, conjugate vaccines are vital for controlling antibiotic-resistant pneumococcal strains.

Related Experiment Videos